Pfizer Inc (PFE)

pos +0.00
Today's Range: 32.43 - 32.95 | PFE Avg Daily Volume: 49,137,100
Last Update: 04/29/16 - 4:01 PM EDT
Volume: 0
YTD Performance: 0.00%
Open: $0.00
Previous Close: $32.91
52 Week Range: $28.25 - $36.46
Oustanding Shares: 6,184,139,991
Market Cap: 203,520,047,104
6-Month Chart
TheStreet Ratings Grade for PFE
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 8 7 7 8
Moderate Buy 0 0 0 1
Hold 5 3 3 3
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.77 1.60 1.60 1.54
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 0.00
Price Earnings Comparisons:
PFE Sector Avg. S&P 500
0.00 29.60 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
0.00% 0.00% 0.00%
Revenue -1.50 -0.20 -0.06
Net Income -23.80 -0.30 -0.10
EPS -21.70 -0.40 -0.17
Earnings for PFE:
Revenue 48.85B
Average Earnings Estimates
Qtr (03/16) Qtr (06/16) FY (12/16) FY (12/17)
Average Estimate $0.55 $0.58 $2.29 $2.54
Number of Analysts 9 6 10 9
High Estimate $0.56 $0.60 $2.33 $2.69
Low Estimate $0.53 $0.56 $2.26 $2.34
Prior Year $0.51 $0.56 $2.20 $2.29
Growth Rate (Year over Year) 7.19% 4.46% 4.27% 10.53%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
Apr 28, 2016 | 7:02 AM EDT
PFE - Pfizer Inc Annual Shareholders Meeting - 8:30AM
After the thwarted Pfizer merger, the generic drug business sale will supply plenty of "ammo."
After the thwarted Pfizer merger, the generic drug business sale will supply plenty of "ammo."
Continuing loan-loss-provision increases. Difficult capital markets (i.e., slow transaction activity and a weak IPO market). Softer merger-and-acquisition activity, hurt by political and geopolitical events, as well as the Justice Department's recent actions against
The oversold biotech sector is recovering.
Pharma and biotech giants now must look to small- and mid-caps to fill out pipelines and bolster growth.
Billionaire Bill Ackman's recent appointment to the troubled drugmaker's board could signal a meanful change of direction.

Columnist Conversations

Mine and many other reviews of the meeting coming Monday, but the quick highlights to whet your appetite: 1)...
Up in an hour or so! Enjoy your weekend and thanks for reading my Diary.
HIG, the object of my affection today, rips +$0.50 higher in the last few minutes of trading. Just wishing and...
Rolling SDS long sale proceeds into SPY/QQQ $2.5 billion to buy at month end, aiding markets. Trying to be opp...


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.